Skip to main content
spacbrain

VG Acquisition Corp.

VGAC · NYSE · formerly 23andMe Holding Co.

Trust settledChrome Holding Co. · Finished

NO ACTION REQUIRED

Nothing left to do

The purchase completed and the shares became shares in the company it bought. There is no deadline left to miss.

Cash at settlement

no closing figure

No cash-per-share figure was filed for this vehicle before it finished.

Last close

no quote on file

Daily close

Nothing left to claim

this vehicle finished

There is nothing to hand back: holders who wanted cash elected it at the vote, and the rest became shares in the buyer.

Read what happened to the cash

The floor

Trust settled

This SPAC has finished — its trust was paid out or used to close the deal, so there is nothing left to redeem

Read the reasoning behind this verdict

No price history on file yet — daily closes accumulate from the market data feed.

Trust settled · There is no line to draw here. This vehicle has finished: the cash was paid back or spent closing the deal, so the last filed figure describes an account that no longer exists and would be a floor under nothing.

SpacBrain’s read

Trust settled

The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

In plain terms

What it is
A SPAC, listed on NYSE in October 2020.
What it's doing now
It agreed to buy Chrome Holding Co., a direct-to-consumer genetic testing and therapeutics company. That purchase completed, and it stopped being a SPAC — the shares became shares in the business it bought.
What you should know
This SPAC has finished. The purchase completed, and the shares became shares in the company it bought — anyone who wanted the cash instead asked for it at the vote, so there is no cash left here to claim and no deadline left to miss.

At a glance

Where it stands
Closed (deSPAC)
The business it bought
Chrome Holding Co.
Industry
Health Care — direct-to-consumer genetic testing and therapeutics
Deal value
not stated in the filings we hold
Price vs cash at settlement
no live price on file
Cash in trust when it settled
not yet extracted into a snapshot — the filings below may state it
the last trust total filed while this was still a SPAC — the account has since been paid out or used to close the deal
IPO
5 October 2020
size not on file
Headquarters
870 MARKET STREET, SAN FRANCISCO, CA, 94102
registered in Delaware
Lead underwriter
not extracted from the prospectus yet
Key officers
Wojcicki Anne (Director) · Selsavage Joseph Anthony (CEO, CFO & CAO) · Kvarda Matthew (Chief Restructuring Officer)
Listed securities
VGAC common
Cash held per sharenot filed for this window

This vehicle has finished, so there is no window to file a cash-per-share figure for and none will follow. No estimate is shown in its place.

Next date that mattersno dated event on file

Nothing dated is on file. That is an absence in the record, not a statement that nothing is coming.

Yield to redemption

Nothing left to redeem — no yield to compute.

This SPAC has finished — its trust was paid back or used to close the deal, so there is nothing left to redeem and no yield to compute. A yield to redemption is a claim that you can hand these shares back for the trust cash. That account is closed, so this page will not print a number here.

What happened to the cash

The reasoning behind the verdict above, in the order the filings establish it.

  1. The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

What has happened, and what is coming

1 dated milestone

Every dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.

  1. 5 October 2020IPOpassed

    IPO size not on file

The deal

terms as filed

What it is buying, on what terms, and how much of the combined company new shares take from you.

  • Chrome Holding Co.—
    closedHealth Care
    Deal structureSEC-primary — BCA 8-K / S-4 / DEFM14A
    PIPE
    ≈ $250M · unsourced

    PIPE terms — instrument, coupon, conversion price and any reset floor — are not sourced for this deal. The size above is itself unsourced — a stored figure no filing we hold states — so neither the size nor the terms should be read as cited.

    stated in:0001193125-21-096583 opens on sec.gov in a new tab

The score

deterministic, from filed fields

VGAC is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.

Asymmetric return scoreNeither a price nor a cash-per-share figure is on file for this vehicle, and the score is a ratio between the two. Nothing is estimated to fill the gap.

The score is only published for names that carry both a price and a filed cash-per-share figure — 292 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.

See the names that are scored, and how

The company

from SEC filings
Read the full profile

VG Acquisition Corp. was a blank-check company whose common stock traded on the New York Stock Exchange under the ticker VGAC. The company priced its initial public offering on October 5, 2020, under SEC file number 333-248844. Its SEC filings were assigned CIK 0001804591 and SIC industry code 2834 for Pharmaceutical Preparations. The vehicle completed a business combination and is now closed, as established by an 8-K filing on June 21, 2021, reporting a change in shell company status. EDGAR now files this CIK under the name Chrome Holding Co.

Material findings

from the full read of every filing

Every document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.

  • DEFM14A17 May 20210001193125-21-162292opens on sec.gov in a new tab

    The Class B block of 313,297,248 shares is nearly as large as the Class A block, and it is created for 23andMe's own holders — so control of the combined company is settled by the share classes rather than at the meeting. The merger consideration is set against an implied equity value of $3.6 billion and converted at a Share Conversion Ratio defined in the merger agreement. At the domestication both VGAC Class A and Class B ordinary shares become one class of New 23andMe Class A stock, and an unseparated unit yields one share plus one-third of a warrant exercisable at $11.50.

  • S-4/A13 May 20210001193125-21-159847opens on sec.gov in a new tab

    The target's holders take a supervoting class: 136,521,838 shares of 23andMe Class B common stock — including 91,198,378 issued on conversion of 23andMe preferred immediately before the merger — become 315,501,968 shares of New 23andMe Class B, against only 20,875,134 Class A shares for 23andMe's Class A holders. The SPAC's own side is 50,855,000 Class A ordinary shares from the IPO units and 12,713,750 Class B shares held by VG Acquisition Sponsor LLC, with warrants split 16,951,666 public and 8,113,999 private placement.

  • S-4/A5 May 20210001193125-21-150945opens on sec.gov in a new tab

    The register is dominated by one class: 313,297,248 New 23andMe Class B shares are issued in respect of 136,156,996 shares of 23andMe Class B common stock — a figure that itself includes 91,198,378 shares arising from the conversion of 23andMe preferred stock immediately before the merger — against only 20,430,501 Class A shares for 8,878,966 shares of 23andMe Class A common stock. The SPAC's own contribution is 50,855,000 Class A ordinary shares from its IPO and 12,713,750 Class B shares held by VG Acquisition Sponsor LLC.

  • S-426 March 20210001193125-21-096583opens on sec.gov in a new tab

    Almost all of the register goes to one class: 313,297,248 New 23andMe Class B shares are issued in respect of 136,156,996 shares of 23andMe Class B common stock — a figure that itself includes 91,198,378 shares arising from the conversion of 23andMe preferred stock immediately before the merger — against only 20,430,501 Class A shares for 8,878,966 shares of 23andMe Class A common stock. The SPAC's own contribution is 50,855,000 Class A ordinary shares from its IPO and 12,713,750 Class B shares held by VG Acquisition Sponsor LLC.

Filings

live EDGAR feed

Everything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.

Show the other 10 filings

The record

The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.

Show the reference detail

Unit structure

Cash in trust at IPOnot extracted from the prospectus

Unit: U = S + W/3

from 424B3 0001193125-23-058315

Trading & liquidity

Average daily volume (20d)no volume reported on the bars we hold
Average daily $ volumeneeds both volume and a live price
Range over the bars heldnot enough price history
Total cash in trustthe trust total is not in the last XBRL stamp

Company profile

Industry (SIC)Pharmaceutical Preparations (2834)
Registered inDelaware
Exchange · CIKNYSE · 0001804591

All filings on EDGARopens on sec.gov in a new tab

Formerly23andMe Holding Co.

Directors & officers

Institutional holders

from SC 13G/13D

Funds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.

Show the declared stakes

12 filers with a stake on file · 0 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.

One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.

News

company wires and the financial press

Reporting we have matched to this ticker. Headlines belong to the outlets that wrote them.

Show the headlines

Sources on file

harvested pages, kept in full

Every public page we have read about this company, stored in full so a source can never go missing.

Show the sources

36 full SEC filing texts archived — searchable, never lost.

In plain English

tap a term to open it

Every piece of jargon this page could have used, and what it actually means.

Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected

A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.

Redemption deadlinethe last day to hand shares back for cash

Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.

Broker action datethe day your broker needs the instruction — earlier than the official date

Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.

Cash in trust / trust per sharethe cash the company is holding for each public share

Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.

Trust discountbuying below the cash held for you

Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.

Dilutionhow much of the company new shares take from you

Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.

Pro-forma equitywhat the company is valued at once the deal closes

The combined company's equity value assuming the announced terms and the redemptions that have actually happened.

ARShow much upside you get per unit of downside

SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.

De-SPACthe day the SPAC becomes the real company

The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.

Outside datethe contractual long-stop for closing the deal

A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.

Accession numberthe SEC's unique id for one filing

Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.

Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since

A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.

Ask the brain

from its filings
Data provenance & audit trail5 internal entries

Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.

VGAC — company record
UNIVERSE-IPO-INDEX2026-08-17

admitted from EDGAR's QUARTERLY FORM INDEX, walked without any SIC filter. The SIC 6770 census could not reach this registrant: EDGAR reassigns a shell's SIC the day it stops being one, and this CIK now files under 2834 (Pharmaceutical Preparations). The screen found it by filing SHAPE instead — S-1 2020-09-16 → 8-A12B 2020-10-01 → 424B4 2020-10-05 — which nothing rewrites. Admission rule: src/lib/universe-admit.ts. SIC 2834 + self-described blank check in 424B4 0000950103-20-019640; 424B 0000950103-20-019640 priced 2020-10-05 under S-1 0000950103-20-018108 (file 333-248844, an offering for cash); common ticker VGAC off 10-K 0001193125-21-092793 (2021-03-24); lifecycle EXITED. The pricing prospectus was filed under SEC file number 333-248844, which belongs to S-1 0000950103-20-018108 (2020-09-16) — a registration of shares sold for CASH, which is what makes it an IPO rather than merger consideration. Blank-check status from the registrant's own first-person sentence in that prospectus (EDGAR full-text search, 424B4 2020-10-05). Ending PROVEN, not inferred: CLOSED per 8-K 0001193125-21-194255 (2021-06-21) — 8-K item 5.06 "Change in Shell Company Status" (EDGAR item index, items: 1.01,2.01,3.02,5.01,5.02,5.05,5.06,9.01). EDGAR now files this CIK as "Chrome Holding Co." — the SPAC's own name is kept here and the successor is the target. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

Deal — Chrome Holding Co.
UNTAGGED

[CLOSED-RENAME] EDGAR CIK 0001804591 records "VG Acquisition Corp." ending 2021-06-17; the registrant continues as "Chrome Holding Co.". The rename is the SEC's own record of what the vehicle became, keyed by CIK. Closed 2021-06-17. No deal value is set — a rename says what was acquired, never for how much. No date column is set: Deal has announcedAt, voteDate and expectedCloseAt and nowhere to record an actual close, so the SEC's date is kept here until that column exists. [DEAL-STRUCTURE-MINED] pipeSizeM=250 from primary filings (0001193125-21-096583).

PROFILE-STUB2026-08-25

entity created from the filed target name; no About paragraph on file, so every other field awaits a sourced read

PIPE2026-08-29

pipeBasis set to UNSOURCED: the size came from the research seed / an earlier record and no filing we hold states it — surfaces now label it "unsourced"; an LLM re-read to FILED replaces this when credits allow

SEGMENT-FROM-FILING2021-05-17

OTHER -> BIOTECH, on DEFM14A 0001193125-21-162292: "23andMe was the first direct-to-consumer genetic testing company to include FDA-authorized genetic health risk, carrier status and pharmacogenetic reports."

Also listed inSPACs with warrants
Back to the screenerVault note